9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II
Reports Second Quarter 2025 Financial Results and Operational Highlights
Shareholder votes
Announces Strategic Royalty Monetization Agreement for Up to $250 Million
Earnings Release
Annual Report to Security Holders
Announces Closing of Strategic Partnership for MPS Diseases
Q2
Q1
FY 2024
FY 2023
Q3
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Post-Effective Amendment to Registration Statement
Automatic Shelf Registration Statement